{
    "clinical_study": {
        "@rank": "166400", 
        "arm_group": {
            "arm_group_label": "Treatment (MR-thermal image guided LITT)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo MR-thermal image guided LITT over 1 hour."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies magnetic resonance thermal image guided laser interstitial\n      thermal therapy in treating patients with breast cancer. Magnetic resonance thermal image\n      guided laser interstitial thermal therapy may be able to kill tumor cells by heating up the\n      tumor cells without affecting the surrounding tissue"
        }, 
        "brief_title": "Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating Patients With Breast Cancer", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ductal Breast Carcinoma in Situ", 
            "Invasive Ductal Breast Carcinoma", 
            "Stage IA Breast Cancer", 
            "Stage IB Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Carcinoma", 
                "Carcinoma in Situ", 
                "Carcinoma, Intraductal, Noninfiltrating", 
                "Carcinoma, Ductal, Breast"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To evaluate the procedural success rate of using the Visualase magnetic resonance\n      (MR)-guided laser system to target, access, thermally monitor, and focally ablate MR-visible\n      breast cancer lesions.\n\n      2. To obtain preliminary data on ablative success using pathologic assessment for specimen\n      excised subsequent to the ablation.\n\n      OUTLINE:\n\n      Patients undergo MR-thermal image guided laser interstitial thermal therapy (LITT) over 1\n      hour.\n\n      After completion of study treatment, patients are followed up at 3-7 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Postmenopausal state\n\n          -  Histological diagnosis of breast invasive ductal carcinoma with receptor profiles\n             obtained\n\n          -  MRI visible breast lesion\n\n          -  Unifocal cancer, less than 1.5 cm in maximum diameter (clinical stage T1), with no\n             evidence of extensive in situ cancer surrounding the main tumor; the eligibility will\n             be determined by the MR imaging appearance of the tumor; if the tumor (proven\n             invasive ductal carcinoma) is a unifocal mass without additional enhancement, it will\n             be judged eligible; however, if the tumor is associated with additional enhancement\n             and/or a satellite focus, it will not judged ineligible, as these are signs of\n             additional in situ or invasive cancer\n\n          -  Clinical stage N0 (no metastatic axillary lymph node on physical examination or\n             imaging work-up)\n\n          -  Ability to give informed consent\n\n        Exclusion Criteria:\n\n          -  Previous surgery or radiation for the ipsilateral breast cancer\n\n          -  Presence of any condition (e.g., metal implant, shrapnel) not compatible with MRI\n\n          -  Tumor located less than 1 cm from the skin or the pectoralis muscle"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01791998", 
            "org_study_id": "12-1017", 
            "secondary_id": "NCI-2013-00066"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (MR-thermal image guided LITT)", 
                "description": "Undergo MR-thermal image guided LITT", 
                "intervention_name": "magnetic resonance thermal imaging", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Treatment (MR-thermal image guided LITT)", 
                "description": "Undergo MR-thermal image guided LITT", 
                "intervention_name": "laser interstitial thermal therapy", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 12, 2014", 
        "location": {
            "contact": {
                "email": "habe@radiology.bsd.uchicago.edu", 
                "last_name": "Hiroyuki Abe", 
                "phone": "773-702-2781"
            }, 
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60637-1470"
                }, 
                "name": "University of Chicago Comprehensive Cancer Center"
            }, 
            "investigator": {
                "last_name": "Hiroyuki Abe", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study to Evaluate Magnet Resonance Thermal Imageguided Interstital Thermal Therapy for Focal Ablation of Breast Cancer", 
        "overall_official": {
            "affiliation": "University of Chicago Comprehensive Cancer Center", 
            "last_name": "Hiroyuki Abe", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Frequency of not completing the procedure due to patient's discomfort", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 days"
            }, 
            {
                "description": "Moderate degree of skin burn which requires medical intervention will be considered side effects for stopping purposes.", 
                "measure": "Observed thermal damage on skin", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 7 days"
            }, 
            {
                "measure": "Grade 3 or 4 toxicities assessed by the National Cancer Institute (NCI) Common Toxicity Criteria (CTC)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 7 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01791998"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Amount of tumor necrosis", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 days"
            }, 
            {
                "measure": "Amount of viable tumor", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 days"
            }
        ], 
        "source": "University of Chicago", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Chicago", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}